Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System
Zydus Lifesciences Ltd 路 Press Release 路 21 Oct 2026, 4:42 pm
Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System Zydus Lifesciences received final USFDA approval for its generic Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg/day), referenced to Climara Pro. Designated as a Competitive Generic Therapy (CGT), the product is eligible for 180 days of marketing exclusivity upon commercial launch. Indicated for menopause symptoms and osteoporosis prevention, it will be manufactured at Moraiya, Ahmedabad. The drug registered annual US sales of ~$45.7 mn (IQVIA MAT Aug'26). As of 30th Sep'26, Zydus holds 458 USFDA approvals and 516 filed ANDAs.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
